Entera Bio (NASDAQ:ENTX) Issues Earnings Results
Entera Bio (NASDAQ:ENTX) reported quarterly earnings of ($0.06) EPS, surpassing analysts' expectations of ($0.08) by $0.02. The stock traded down $0.05 to $1.75 with a market cap of $62.62 million. Analysts at HC Wainwright maintained a "buy" rating with a price target of $10.00. Entera Bio focuses on developing orally delivered peptide and protein therapeutics, with candidates in clinical trials for hypoparathyroidism and osteoporosis.
Entera Bio (NASDAQ:ENTX - Get Free Report) announced its quarterly earnings results on Friday. The company reported ($0.06) earnings per share for the quarter, beating analysts' consensus estimates of ($0.08) by $0.02, Zacks reports.
Entera Bio Price Performance
Shares of NASDAQ ENTX traded down $0.05 during mid-day trading on Friday, hitting $1.75. The company's stock had a trading volume of 55,218 shares, compared to its average volume of 120,233. The stock has a market cap of $62.62 million, a price-to-earnings ratio of -6.73 and a beta of 1.62. The company's fifty day simple moving average is $2.15 and its 200-day simple moving average is $2.02. Entera Bio has a one year low of $1.41 and a one year high of $3.35.
Analysts Set New Price Targets
Separately, HC Wainwright restated a "buy" rating and issued a $10.00 price objective on shares of Entera Bio in a research report on Tuesday, March 18th.
Read Our Latest Report on Entera Bio
About Entera Bio
(Get Free Report)Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures.
Recommended Stories
- Five stocks we like better than Entera Bio
- What is a Death Cross in Stocks?
- Why Dollar Tree’s Family Dollar Sale Could Spark a Comeback
- Upcoming IPO Stock Lockup Period, Explained
- JPMorgan: The 'NVIDIA of Banking' Poised for More Gains?
- Expert Stock Trading Psychology Tips
- Buy the Chewy Stock Reversal? Here’s Why Now Is the Time
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Should You Invest $1,000 in Entera Bio Right Now?
Before you consider Entera Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Entera Bio wasn't on the list.
While Entera Bio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
